Rona Therapeutics grants Roche worldwide rights to an ALK7-silencing candidate, with up to $1.06b in further milestones on ...

Insilico Medicine nominates ISM9546, an oral VAV1 degrader designed with generative AI, as a preclinical candidate for ...

As pharma shops for de-risked science, venture money is moving later and concentrating in fewer, bigger bets – our report ...

Nature Biotechnology paper offers a better way to judge models that predict gene effects. Shift plans to use it to hunt for ...

KAUST and Oxford researchers used a transistor-based sensor to read three forms of alpha-synuclein, reaching 90.9% accuracy ...

Cala Health’s kIQ Plus now offers three stimulation modes and a calibration before each use, and it’s available across the US ...

A day is a long time to study a donated human brain. Bexorg thinks it’s still too short. On 7 October, the Connecticut-based ...

Adjusting for how advanced patients’ disease was at the start lifts the Phase 2 result. The method was added after the trial ...

German biotech MODAG won for pairing a CE-marked diagnostic with a drug candidate that targets the same protein.

Buck Institute’s Eric Verdin joins clinic leaders to tackle the ‘luxury diagnostic’ trap and the push for standardized care.

Shmouni and Koehl Robinson unpack peptide medicine, from GLP-1s and BPC-157 to evidence, safety, regulation and personalized ...

BodySpec’s new storefront targets muscle loss from GLP-1 weight loss drugs, with scans said to take about 12 minutes.